Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx
Conditions
Brief summary
This phase II trial studies nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation) and carboplatin followed by response-based local therapy in treating patients with stage III or IV human papillomavirus (HPV)-related oropharyngeal cancer. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, carboplatin, hydroxyurea, fluorouracil, paclitaxel, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them spreading. Radiation therapy uses high energy x rays to kill tumor cells. Giving nab-paclitaxel and carboplatin before chemoradiation may make the tumor smaller and reduce the amount of chemotherapy and radiation therapy needed. Assigning chemotherapy and radiation therapy based on response (response-based therapy) and giving patients who are responding well lower doses of treatment may help reduce the occurrence of side effects.
Detailed description
PRIMARY OBJECTIVES: I. To determine the 2-year progression-free survival (PFS). SECONDARY OBJECTIVES: I. Clinical complete response rate (nab-paclitaxel based induction, compared to European Prospective Investigation into Cancer and Nutrition \[EPIC\] induction \[paclitaxel based\]). II. Response rate (nab-paclitaxel based induction, compared to EPIC induction \[paclitaxel based\]). III. Proportion of patients with \>= 50% shrinkage by Response Evaluation Criteria In Solid Tumors (RECIST) (nab-paclitaxel based induction, compared to EPIC induction, paclitaxel based). IV. Toxicity (nab-paclitaxel based induction, compared to EPIC induction \[paclitaxel based\]). V. To assess swallowing function and speech at 6 months (mos) and 12 mos post therapy. VI. To determine the rates of late toxicity with chemoradiation following surgery as determined by xerostomia, dental decay, osteroradionecrosis, G-tube dependency, tracheostomy placement and dysphagia. VII. 2-year overall survival (OS) in patients treated on the Low-Risk, Intermediate-Risk Arm, and High-Risk Arms. VIII. 2-year PFS in patients treated on the Low-Risk, Intermediate-Risk Arm, and High-Risk Arms - early and late toxicities. IX. Evaluate need for post radiotherapy/chemoradiotherapy (RT/CRT) surgery on low- and intermediate-risk arms based on response from induction chemotherapy. X. Evaluate in a descriptive manner the role of transoral robotic surgery (TORS) resection/lymph node dissection (LND) when integrated into a de-escalation trial. TERTIARY OBJECTIVES: I. To evaluate pathologic/histologic appearance of tumor after induction chemotherapy and after CRT. II. Translational research on blood and tissue samples. III. To profile tumors genetically and immunologically in order to assess in a descriptive manner genetic or immunological features characteristic of clinical behavior. OUTLINE: INDUCTION CHEMOTHERAPY: All patients receive paclitaxel albumin-stabilized nanoparticle formulation intravenously (IV) over 60 minutes on days 1, 8, and 15 and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients are then assigned to 1 of 3 treatment groups based on response to induction chemotherapy. GROUP A (LOW-DOSE ARM): Patients undergo radiation therapy once daily for 5 weeks. GROUP B (INTERMEDIATE-DOSE ARM): Patients receive hydroxyurea orally (PO) twice daily (BID) on days 0-5, fluorouracil IV continuously on days 1-5, and paclitaxel IV over 60 minutes on day 1. Patients also receive low-dose radiation therapy BID on days 1-5. Treatment repeats every 14 days for 3 courses in the absence of disease progression or unacceptable toxicity. GROUP C (STANDARD-DOSE ARM): Patients receive hydroxyurea PO BID on days 0-5, fluorouracil IV continuously on days 1-5, and paclitaxel IV over 60 minutes on day 1. Patients also receive standard-dose radiation therapy BID on days 1-5. Treatment repeats every 14 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.\* \*NOTE: At the discretion of the principal investigator (PI), patients may receive cisplatin IV over 1-3 hours every 3 weeks during radiation therapy instead of paclitaxel and undergo daily radiation therapy. After completion of study treatment, patients are followed up for 30 days, every 3 months for 1 year, every 6 months for 2 years, and then annually for 2 years.
Interventions
DRUGpaclitaxel albumin-stabilized nanoparticle formulation
Given IV
DRUGcarboplatin
Given IV
RADIATIONradiation therapy
Undergo radiation therapy
DRUGpaclitaxel
Given IV
DRUGfluorouracil
Given IV
DRUGhydroxyurea
Given PO
DRUGcisplatin
Given IV
OTHERlaboratory biomarker analysis
Correlative studies
PROCEDUREquality-of-life assessment
Ancillary studies
Sponsors
National Cancer Institute (NCI)
University of Chicago
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have pathologically confirmed HPV-positive squamous cell carcinoma * HPV testing must follow the following criteria * HPV testing using an E6/E7 based assay is preferred, and does not require any validation (e.g. HPV in situ hybridization \[ISH\] or HPV E6/E7 polymerase chain reaction \[PCR\]) * For oropharyngeal tumors p16 immunohistochemistry (IHC) positivity is sufficient to enroll and initiate treatment (p16 IHC interpretation to follow guidelines by Jordan/Lingen et al 2012); it is recommended that p16 IHC positivity is validated at a later point (during or after treatment) using an E6/E7 based test at the University of Chicago and provided slides will be used * For non-operative (OP) tumors accurate HPV testing (i.e. ISH, or E6/E7 based testing) is required for enrollment and treatment initiation * Availability of \>= 10 unstained 5 micron slides * Patients with American Joint Committee on Cancer (AJCC) (7th edition, 2010) nodal stage N2 or N3 or a T4 primary tumor * The primary and nodal involvement must be assessable on clinical exam (mucosal and lymph node exam) * The primary and nodal involvement must have been defined bi- or uni-dimensional measurements measurable by RECIST * No previous radiation or chemotherapy for a head and neck cancer * No surgical resection for a head and neck cancer within 8 weeks of enrollment (although lymph node biopsy including excision of an individual node with presence of residual nodal disease, or surgical biopsy of the tumor is acceptable) * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (Karnofsky \>= 70%) * Leukocytes \>= 3000/mm\^3 * Platelets \>= 100,000/mm\^3 * Absolute neutrophil count \>= 1,500 * Hemoglobin \> 9.0 gm/dL * Albumin \> 2.9 gm/dL * Total bilirubin =\< 1.5 mg/dl * Creatinine clearance \> 45 mL/min (or serum creatinine \[SCr\] =\< 1.5 mg/dL), normal within 2 weeks prior to start of treatment * The standard Cockcroft and Gault formula or the measured glomerular filtration rate must be used to calculate creatinine clearance (CrCl) for enrollment or dosing * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 2.5 X upper limit of normal (ULN) * Alkaline phosphatase =\< 2.5 X ULN * Patients must sign a study-specific informed consent form prior to study entry; patients should have the ability to understand and the willingness to sign a written informed consent document
Exclusion criteria
* Unequivocal demonstration of distant metastases (M1 disease) * Intercurrent medical illnesses which would impair patient tolerance to therapy or limit survival; including but not limited to ongoing or active infection, immunodeficiency, symptomatic congestive heart failure, pulmonary dysfunction, cardiomyopathy, unstable angina pectoris, cardiac arrhythmia or psychiatric illness/social situations that would limit compliance * Pregnant and nursing women are excluded; men and women of child-bearing potential are eligible but must consent to using effective contraception during therapy and for at least 3 months after completing therapy; women with child-bearing potential must have a negative serum or urine beta-human chorionic gonadotropin (B-hCG) pregnancy test at screening * Other coexisting malignancies or malignancies diagnosed within the previous 3 years no evidence of disease for at least 3 years; exceptions to this include non-melanoma skin cancer, cervical cancer in situ, well differentiated thyroid cancer or prostate cancer; other cancers that per assessment of the PI are not prognosis limiting can be allowed after review by the PI * Prior surgical therapy other than incisional or excisional biopsy and organ-sparing procedures such as debulking of airway-compromising tumors or neck dissection in a patient with an unknown primary tumor; residual tumor is required for enrollment on study * Patients receiving other investigational agents * Peripheral neuropathy \>= grade 1
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-Free Survival (PFS), Evaluated Using RECIST Version (v) 1.1 | Time from enrollment until disease progression or death from any cause, assessed at 2 years | If all patients are followed for two years, the PFS rate and confidence interval will be determined based on the exact binomial distribution. Otherwise, PFS will be estimated using the Kaplan-Meier method and a (large-sample) one-sided 90% confidence interval will be derived for the PFS rate at two years to test the non-inferiority hypothesis. Median PFS will be estimated as described in Brookmeyer and Crowley. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival | From the date of registration to the date of death or date of last patient contact if censored, assessed up to 5 years | Overall survival rate |
| Cancer-specific Survival | Up to 5 years | Overall Cancer-specific survival rate. Patients dying from non-cancer related causes will be censored at the time of death. |
| Rates of Acute Toxicity, Determined by Incidence of Mucositis, Xerostomia, Anorexia, Weight Loss, Dermatitis and G-tube Placement | Up to 5 years | Toxicity rates will be summarized by type of toxicity, grade, and attribution. The incidence of acute (mucositis, xerostomia, anorexia, weight loss, dermatitis and G-tube placement) toxicities will be estimated along with 95% confidence intervals. Toxicity criteria of the Common Toxicity Criteria (CTC) and the Radiation Therapy Oncology Group (RTOG) will be used to determine grades. General CTC grade definitions: 0 = No adverse event or within normal limits; 1 = Mild adverse event; 2 = Moderate adverse event; 3 = Severe and undesirable adverse event; 4 = Life-threatening or disabling adverse event; 5 = Death related to adverse event. For Mucous, 3 = Confluent fibrinous, mucositis / may include severe pain requiring narcotic; 4 = Ulceration, hemorrhage or necrosis. For neutropenia, 3 = Neutrophils 0.5 - \< 1.0; 4 = Neutrophils \< 0.5 or sepsis. |
| Rates of Late Toxicity, Determined by Incidence of Xerostomia, Dental Decay, Osteroradionecrosis, G-tube Dependency, Tracheostomy Placement and Dysphagia | Up to 5 years | Toxicity rates will be summarized by type of toxicity, grade, and attribution. The incidence of late-term (xerostomia, dental decay, osteroradionecrosis, G-tube dependency, speech abnormalities, tracheostomy placement and dysphagia) toxicities will be estimated along with 95% confidence intervals. |
| Rate of Pathologic Complete Response (PCR) on Post Treatment Biopsy/Surgery, Evaluated Using RECIST v1.1 | Up to 8 weeks after completion of CRT | Pathologic response rates will be determined and 95% confidence intervals obtained using the exact binomial distribution. |
| Clinical Complete Response by Computerized Tomography (CT) & Magnetic Resonance Imaging (MRI) Only | Up to 5 years | Clinical response rates will be determined and 95% confidence intervals obtained using the exact binomial distribution. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Changes in Reactive T Cells | Baseline to up to 2 months after radiation therapy | Changes in reactive T cells over time will be assessed using mixed effects models and simple paired t-tests. |
| Histologic Appearance of Post-induction Tumor Tissue | Up to 3 months post-treatment | Results of pathology/histologic review of post induction biopsy specimens will be descriptive and summarize in tabular format. |
| Histologic Appearance of Post-CRT Tumor Tissue | Up to 3 months post-treatment | Results of pathology/histologic review of post induction biopsy specimens will be descriptive and summarize in tabular format. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Single Arm Radiation therapy alone, combination chemotherapy with low-dose radiation therapy, or combination chemotherapy with high-dose radiation | 62 |
| Total | 62 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Withdrawal by Subject | 1 |
Baseline characteristics
| Characteristic | Single Arm |
|---|---|
| Age, Continuous | 60 years |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 2 Participants |
| Race (NIH/OMB) Black or African American | 4 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 56 Participants |
| Sex: Female, Male Female | 3 Participants |
| Sex: Female, Male Male | 59 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 5 / 62 |
| other Total, other adverse events | 60 / 62 |
| serious Total, serious adverse events | 5 / 62 |
Outcome results
Primary
Progression-Free Survival (PFS), Evaluated Using RECIST Version (v) 1.1
If all patients are followed for two years, the PFS rate and confidence interval will be determined based on the exact binomial distribution. Otherwise, PFS will be estimated using the Kaplan-Meier method and a (large-sample) one-sided 90% confidence interval will be derived for the PFS rate at two years to test the non-inferiority hypothesis. Median PFS will be estimated as described in Brookmeyer and Crowley.
Time frame: Time from enrollment until disease progression or death from any cause, assessed at 2 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Single Arm | Progression-Free Survival (PFS), Evaluated Using RECIST Version (v) 1.1 | 94.5 percentage of participants |
Secondary
Cancer-specific Survival
Overall Cancer-specific survival rate. Patients dying from non-cancer related causes will be censored at the time of death.
Time frame: Up to 5 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Single Arm | Cancer-specific Survival | 95 percentage of participants |
Secondary
Clinical Complete Response by Computerized Tomography (CT) & Magnetic Resonance Imaging (MRI) Only
Clinical response rates will be determined and 95% confidence intervals obtained using the exact binomial distribution.
Time frame: Up to 5 years
Population: one missing value
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Single Arm | Clinical Complete Response by Computerized Tomography (CT) & Magnetic Resonance Imaging (MRI) Only | complete response | 13 percentage of participants |
| Single Arm | Clinical Complete Response by Computerized Tomography (CT) & Magnetic Resonance Imaging (MRI) Only | Partial Response | 80 percentage of participants |
| Single Arm | Clinical Complete Response by Computerized Tomography (CT) & Magnetic Resonance Imaging (MRI) Only | Stable Disease | 13 percentage of participants |
Secondary
Overall Survival
Overall survival rate
Time frame: From the date of registration to the date of death or date of last patient contact if censored, assessed up to 5 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Single Arm | Overall Survival | 87 percentage of participants |
Secondary
Rate of Pathologic Complete Response (PCR) on Post Treatment Biopsy/Surgery, Evaluated Using RECIST v1.1
Pathologic response rates will be determined and 95% confidence intervals obtained using the exact binomial distribution.
Time frame: Up to 8 weeks after completion of CRT
Population: Ten missing values
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Single Arm | Rate of Pathologic Complete Response (PCR) on Post Treatment Biopsy/Surgery, Evaluated Using RECIST v1.1 | 90 percentage of participants |
Secondary
Rates of Acute Toxicity, Determined by Incidence of Mucositis, Xerostomia, Anorexia, Weight Loss, Dermatitis and G-tube Placement
Toxicity rates will be summarized by type of toxicity, grade, and attribution. The incidence of acute (mucositis, xerostomia, anorexia, weight loss, dermatitis and G-tube placement) toxicities will be estimated along with 95% confidence intervals. Toxicity criteria of the Common Toxicity Criteria (CTC) and the Radiation Therapy Oncology Group (RTOG) will be used to determine grades. General CTC grade definitions: 0 = No adverse event or within normal limits; 1 = Mild adverse event; 2 = Moderate adverse event; 3 = Severe and undesirable adverse event; 4 = Life-threatening or disabling adverse event; 5 = Death related to adverse event. For Mucous, 3 = Confluent fibrinous, mucositis / may include severe pain requiring narcotic; 4 = Ulceration, hemorrhage or necrosis. For neutropenia, 3 = Neutrophils 0.5 - \< 1.0; 4 = Neutrophils \< 0.5 or sepsis.
Time frame: Up to 5 years
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Single Arm | Rates of Acute Toxicity, Determined by Incidence of Mucositis, Xerostomia, Anorexia, Weight Loss, Dermatitis and G-tube Placement | Grade 3+ mucositis | 35 participants |
| Single Arm | Rates of Acute Toxicity, Determined by Incidence of Mucositis, Xerostomia, Anorexia, Weight Loss, Dermatitis and G-tube Placement | Grade 3+ dermatitis | 12 participants |
| Single Arm | Rates of Acute Toxicity, Determined by Incidence of Mucositis, Xerostomia, Anorexia, Weight Loss, Dermatitis and G-tube Placement | grade 3+ neutropenia | 29 participants |
| Single Arm | Rates of Acute Toxicity, Determined by Incidence of Mucositis, Xerostomia, Anorexia, Weight Loss, Dermatitis and G-tube Placement | grade 3+ Anorexia | 5 participants |
Secondary
Rates of Late Toxicity, Determined by Incidence of Xerostomia, Dental Decay, Osteroradionecrosis, G-tube Dependency, Tracheostomy Placement and Dysphagia
Toxicity rates will be summarized by type of toxicity, grade, and attribution. The incidence of late-term (xerostomia, dental decay, osteroradionecrosis, G-tube dependency, speech abnormalities, tracheostomy placement and dysphagia) toxicities will be estimated along with 95% confidence intervals.
Time frame: Up to 5 years
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Single Arm | Rates of Late Toxicity, Determined by Incidence of Xerostomia, Dental Decay, Osteroradionecrosis, G-tube Dependency, Tracheostomy Placement and Dysphagia | G-tube dependence | 18 participants |
| Single Arm | Rates of Late Toxicity, Determined by Incidence of Xerostomia, Dental Decay, Osteroradionecrosis, G-tube Dependency, Tracheostomy Placement and Dysphagia | Dysphagia | 18 participants |
Other Pre-specified
Changes in Reactive T Cells
Changes in reactive T cells over time will be assessed using mixed effects models and simple paired t-tests.
Time frame: Baseline to up to 2 months after radiation therapy
Population: zero analyzed because no data was collected
Other Pre-specified
Histologic Appearance of Post-CRT Tumor Tissue
Results of pathology/histologic review of post induction biopsy specimens will be descriptive and summarize in tabular format.
Time frame: Up to 3 months post-treatment
Population: zero analyzed because no data was collected
Other Pre-specified
Histologic Appearance of Post-induction Tumor Tissue
Results of pathology/histologic review of post induction biopsy specimens will be descriptive and summarize in tabular format.
Time frame: Up to 3 months post-treatment
Population: zero analyzed because no data was collected